Clinical Syndromes and Consequences of Antiretroviral-Related Hepatotoxicity

Department of Internal Medicine, Wake Forest University Health Sciences, Winston Salem, NC 27157, USA.
Hepatology (Impact Factor: 11.06). 09/2010; 52(3):1143-55. DOI: 10.1002/hep.23716
Source: PubMed


Highly active antiretroviral therapy (HAART)-related hepatotoxicity complicates the management of patients infected with human immunodeficiency virus (HIV), increases medical costs, alters the prescription patterns, and affects the guideline recommendations. Among the clinical consequences derived from HAART-related liver toxicity, hypersensitivity reactions and lactic acidosis are recognized as acute events with potential to evolve into fatal cases, whereas there seems to be other syndromes not as well characterized but of equal concern as possible long-term liver complications. Belonging to the latter category of syndrome, HAART-related nonalcoholic steatohepatitis, liver fibrosis, portal hypertension, and nodular regenerative hyperplasia are discussed in this review. Updated information on liver toxicity of current antiretroviral drugs, including the most recently licensed, is provided. Management and prevention of liver toxicity among HIV-infected patients treated with HAART are reviewed as well.

15 Reads
  • Source
    • "However, the need for lifelong therapy and difficulties in adherence to medication regimes are likely to lead to the emergence of drug-resistant HIV-1 strains. Long-term side effects, such as cardiovascular disease, hepatotoxicity and dementia, have been reported in association with HIV-1 infection.4,5,6 The most serious deficiency of ART is that it cannot eradicate latent virus.7 Once the treatment is interrupted, a replicable HIV-1 reemerges. "
    [Show abstract] [Hide abstract]
    ABSTRACT: MazF, an endoribonuclease encoded by Escherichia coli, specifically cleaves the ACA (adenine-cytosine-adenine) sequence of single-stranded RNAs. Conditional expression of MazF under the control of the HIV-1 LTR promoter rendered CD4(+) T cells resistant to HIV-1 replication without affecting cell growth. To investigate the safety, persistence and efficacy of MazF-modified CD4(+) T cells in a nonhuman primate model in vivo, rhesus macaques were infected with a pathogenic simian/human immunodeficiency virus (SHIV) and transplanted with autologous MazF-modified CD4(+) T cells. MazF-modified CD4(+) T cells were clearly detected throughout the experimental period of more than 6 months. The CD4(+) T cell count values increased in all four rhesus macaques. Moreover, the transplantation of the MazF-modified CD4(+) T cells was not immunogenic, and did not elicit cellular or humoral immune responses. These data suggest that the autologous transplantation of MazF-modified CD4(+) T cells in the presence of SHIV is effective, safe and not immunogenic, indicating that this is an attractive strategy for HIV-1 gene therapy.
    Molecular Therapy - Nucleic Acids 06/2014; 3(6):e168. DOI:10.1038/mtna.2014.20 · 4.51 Impact Factor
  • Source
    • "Among the indirect mechanisms, the most important is based on an impaired T-cell response to HCV [4], which can be only partially reverted by antiretroviral treatment [2]; in fact, end-stage liver disease actually represents the leading cause of mortality among HIV-positive patients, regardless of the use of ART [5]. Moreover, HIV itself and certain antiretrovirals may contribute to liver disease by inducing the metabolic syndrome [6]. In addition, HIV infection of the gastrointestinal tract amplifies microbial translocation which can stimulate hepatocytes, Kupffer cells (KCs), and hepatic stellate cells (HSC) to produce pro-inflammatory cytokines and chemokines. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In HIV/HCV co-infected patients, HIV-1 gp120 activates human hepatic stellate cells (HSCs) which play a key role in fibrosis pathogenesis. It is still unclear whether pro-fibrogenic effects are more attributable to X4 or R5 strains in vivo. To assess if HIV-1 X4 or R5 variants are associated with a different progression of fibrosis. A total of 105 HIV/HCV co-infected patients were submitted to gp120 sequencing on proviral DNA and classified as X4 or R5 based on g2p (20% false positive rate). The fibrosis evolution was retrospectively determined by means of APRI and FIB-4 scores at 3-month intervals from the first anti-HCV-positive test. The association of co-receptor tropism with increased fibrosis scores was evaluated by linear mixed models. X4 variants were found in 41 patients (39%). The median observation period was similar in X4 and R5 patients (17 years). No difference was observed between the two groups of patients, except for nadir CD4 which was lower in X4 compared to R5 (percentage, p=0.005, and absolute number, p=0.005). X4 and R5 patients did not significantly differ for FIB-4 and APRI score over time (p=0.5, and p=0.1, respectively). No association between HCV-RNA levels over time and co-receptor tropism was noted (p=0.9). Conversely, a significant correlation of fibrosis scores with gamma-glutamyl transferase levels, lower current CD4 count, HIV viremia and use of antiretrovirals was observed. This retrospective analysis of fibrosis evolution did not support the evidence of a differing pro-fibrogenic activity for X4 and R5 HIV-1 variants in HIV/HCV co-infected patients.
    Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 01/2014; 59(3). DOI:10.1016/j.jcv.2013.12.009 · 3.02 Impact Factor
  • Source
    • "In this sense, the study of Guaraldi et al. (2008) suggested that NAFLD is common in HIV patients who have traditional risk factors but this study also highlights that treatment with NRTIs is also an important independent risk factor, increasing up to 11% the risk of developing hepatic impairment for each year of use [60]. Some protease inhibitors are also hepatotoxic, in particular full-dose ritonavir and tipranavir [61]. However, the generalized use of only boosting concentrations of ritonavir prevents the liver toxicity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Highly active antiretroviral therapy (HAART) has considerably improved the prognosis of HIV-infected patients. However, prolonged use of HAART has been related to long-term adverse events that can compromise patient health such as HIV-associated lipodystrophy syndrome (HALS) and nonalcoholic fatty liver disease (NAFLD). There is consistent evidence for a central role of mitochondrial dysfunction in these pathologies. Nucleotide reverse transcriptase inhibitors (NRTIs) have been described to be mainly responsible for mitochondrial dysfunction in adipose tissue and liver although nonnucleoside transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) have also showed mitochondrial toxicity, which is a major concern for the selection and the long-term adherence to a particular therapy. Several mechanisms explain these deleterious effects of HAART on mitochondria, and evidence points to other mechanisms beyond the “Pol- γ hypothesis.” HIV infection has also direct effects on mitochondria. In addition to the negative effects described for HIV itself and/or HAART on mitochondria, HIV-infected patients are more prone to develop a premature aging and, therefore, to present an increased oxidative state that could lead to the development of these metabolic disturbances observed in HIV-infected patients.
    Oxidative Medicine and Cellular Longevity 07/2013; 2013(12, article 1109):493413. DOI:10.1155/2013/493413 · 3.36 Impact Factor
Show more


15 Reads